Wockhardt seeks DCGI nod for Zaynich
Drugmaker Wockhardt on Friday said that it has filed for regulatory approval of its Zaynich with the Drug Controller General of India (DCGI), with a domestic launch expected in the second half of the current fiscal.
The drugmaker also revealed plans to file New Drug Application (NDA) in USA by August following a successful pre-NDA (non-disclosure agreement) meeting with the US Food and Drug Administration (USFDA). If approved, the company aims for a U.S. launch in FY2026-27.
In addition to India and the U.S., Wockhardt is preparing to seek regulatory approvals in Europe and emerging markets in the second half of the current fiscal year.
The company has an addressable market opportunity of USD 7 billion in the US and Europe.
The outcome of this study reflects the impact of Zaynich’s novel β-lactam enhancer mechanism of action. Additionally, Zaynich was well-tolerated and showed a safety profile consistent with β-lactam class of antibiotics, comparable to meropenem. This study is NDA-enabling, based on which marketing authorization applications will be made to global health authorities including India, US, EMA and MHRA.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.